Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years

Multiple Sclerosis

Volumn 22, Issue 1, 2016, Pages 112-116

  Macmillan, E L ^a   Tam, R ^b   Zhao, Y ^a   Vavasour, I M ^a   Li, D K B ^a   Oger, J ^a   Freedman, M S ^b   Kolind, S H ^a   Traboulsee, A L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

biomarkers; magnetic resonance imaging; Secondary progressive multiple sclerosis

Indexed keywords

CHOLINE; CREATINE; DIRUCOTIDE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER;

ADULT; AMINO ACID BRAIN LEVEL; ARTICLE; BRAIN ATROPHY; BRAIN TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CORTICAL THICKNESS (BRAIN); DISEASE MARKER; DOWN REGULATION; FEMALE; HUMAN; MALE; METABOLITE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; WHITE MATTER; CLINICAL FEATURE; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; MIDDLE AGED; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; AGED; FOLLOW UP; METABOLISM; TIME FACTOR;

ADULT; AGED; BIOMARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TIME FACTORS;

EID: 84951197293     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515586086     Document Type: Article

References (17)

1. Nordengen K, Heuser C, Rinholm JE, et al. Localisation of N -acetylaspartate in oligodendrocytes/myelin. Brain Struct Funct 2015; 220: 899-917.
2. De Stefano N, Filippi M, Miller D, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007; 69: 1942-1952.
3. Kirov II, Tal A, Babb JS, et al. Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology 2013; 80: 39-46.
4. Freedman MS, Traboulsee A, Bar-Or A, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011; 77: 1551-1560.
5. Jones C, Li DKB, Zhao G, et al. Atrophy measurements in multiple sclerosis. In: Proceedings of the 9th scientific meeting of the International Society for Magnetic Resonance in Medicine, Glasgow, Scotland, UK, 21-27 April 2001, paper 1414.
6. Garg S, Traboulsee A, Li DKB, et al. A robust and sensitive voxel-based method for measuring cortical thickness change using fuzzy correspondence. In: XXIV Brazilian congress on biomedical engineering, Uberlândia, Brazil, 13-17 October, 2014, paper 1617-1620.
7. McKenna MC., The glutamate-glutamine cycle is not stoichiometric: Fates of glutamate in brain. J Neurosci Res. 2007; 85: 3347-3358.
8. Hädel S, Wirth C, Rapp M, et al. Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. J Magn Reson Imaging 2013; 38: 1480-1487.
9. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005; 128: 1016-1025.
10. Tisell A, Leinhard OD, Warntjes JBM, et al. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. PLoS One 2013; 8: e61817.
11. Azevedo CJ, Kornak J, Chu P, et al. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol 2014; 76: 269-278.
12. Centonze D, Muzio L, Rossi S, et al. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 2010; 17: 1083-1091.
13. Yeo RA, Gasparovic C, Merideth F, et al. A longitudinal proton magnetic resonance spectroscopy study of mild traumatic brain injury. J Neurotrauma 2011; 28: 1-11.
14. Gajofatto A, Calabrese M, Benedetti MD, et al. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013; 35: 687-699.
15. Sajja BR, Narayana PA, Wolinsky JS, et al. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: Multicenter study. Mult Scler 2008; 14: 73-80.
16. Sajja BR, Wolinsky JS, Narayana PA., Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am. 2009; 19: 45-58.
17. Mader I, Roser W, Kappos L, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: Absolute metabolic values over 2 years during a clinical pharmacological study. Am J Neuroradiol 2000; 21: 1220-1227.